Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Ex-Puma exec charged with insider trading, hit with criminal charges | Fierce Biotech
PumaBiotech (@pumabiotech) / Twitter
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Pharma (@PumaPharma) / Twitter
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma – PHARMA
Puma Biotechnology
Puma – PHARMA
PharmaBg
Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
La EMA recomienda no aprobar el fármaco de Puma Biotech
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma – PHARMA
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma – PHARMA
Puma – PHARMA
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Medical Affairs eLearning - MSL Society
PUMA BIOTECHNOLOGY, INC. : Precios y cotizaciones Acción | PBYI | US74587V1070 | MarketScreener